BIOMAT Database Logo BIOMAT Database Logo

Trend towards decreased survival in patients infected with HIV resistant to zidovudine. 1992

P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.

The survival of 35 patients with AIDS or advanced HIV infection on treatment with zidovudine was related to the viral sensitivity to the drug and to the CD4+ cell count. 14 patients died, the survivors were followed up for an average of 804 days. In a univariate Cox model, survival was strongly related to log IC90 (p = 0.0003) and to the CD4+ count (p = 0.0002). In a bivariate model, log IC90 and the CD4+ count contributed to the prediction of survival (p = 0.12 and 0.06, respectively). Large studies of combination or alternation therapy with several anti-HIV drugs should be given high priority.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte

Related Publications

P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Consent to treatment with zidovudine among HIV-infected patients.
January 1992, Cleveland Clinic journal of medicine,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
[Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
January 1998, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Cytomegalovirus viremia in HIV-infected patients treated with zidovudine.
January 1990, Scandinavian journal of infectious diseases,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine.
July 1990, The New England journal of medicine,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Zidovudine resistant HIV.
April 1989, BMJ (Clinical research ed.),
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Zidovudine available to HIV-infected children.
January 1990, American family physician,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Hematologic toxicity of zidovudine in HIV-infected patients.
May 1990, American family physician,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.
February 1990, The Journal of infectious diseases,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Attitudes towards patients infected with HIV.
December 1987, The Journal of the Royal College of General Practitioners,
P C Gøtzsche, and C Nielsen, and J Gerstoft, and C M Nielsen, and B F Vestergaard
Primary infection with zidovudine-resistant HIV.
October 1993, The New England journal of medicine,
Copied contents to your clipboard!